{
    "clinical_study": {
        "@rank": "99042", 
        "arm_group": [
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Other", 
                "description": "Active control arm, Locatop@, Locapred@"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Other", 
                "description": "Absence of emollient treatment, Locatop@, Locapred@"
            }, 
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "glycerol, paraffin (liquid and white soft), Locatop@\n, Locapred@"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to confirm that emollients play a major role in the maintenance\n      therapy after clearing of inflammatory lesions and can reduce occurrence of flares in\n      children with atopic dermatitis."
        }, 
        "brief_title": "Emollients in the Management of Atopic Dermatitis", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 2 and 6 years included,\n\n          -  Presenting with atopic dermatitis, with at least one duly documented flare treated by\n             corticosteroids within the previous 6 months, and presenting a current flare\n             (objective Scoring for Atopic Dermatitis (SCORAD score) is [15-40] at inclusion),\n\n          -  After treatment of the current flare, patients should have for randomization an\n             Objective SCORAD score < 15, with  Xerosis intensity\u2265 1 and no subjective signs\n\n        Exclusion Criteria:\n\n          -  Severe form of atopic dermatitis requiring either systemic corticosteroid treatment\n             and/or antibiotic or antiviral treatment and/or hospitalisation,\n\n          -  Primary bacterial, viral, fungal or parasitic skin infection,\n\n          -  Ulcerated lesions, acne or rosacea,\n\n          -  Dermatological disease other than atopic dermatitis which could interfere with the\n             assessment,\n\n          -  Immunosuppression,"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "347", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779258", 
            "org_study_id": "V00034 CR 3 13 1B", 
            "secondary_id": "2012-004621-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "description": "1 application in the morning and in the evening", 
                "intervention_name": "glycerol, paraffin (liquid and white soft)", 
                "intervention_type": "Drug", 
                "other_name": "Dexeryl\u00ae"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "1 application in the morning, in the afternoon and in the evening", 
                "intervention_name": "Atopiclair\u00ae", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3"
                ], 
                "description": "During the Run-In period:\n1 application in the morning and in the evening  during a maximum of 21 days", 
                "intervention_name": "Locatop@", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3"
                ], 
                "description": "During the 3 months study treatment:\n1 application in the evening in case of flare \"", 
                "intervention_name": "Locapred@", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Desonide", 
                "Emollients", 
                "Glycerol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "xerosis", 
            "dry skin", 
            "dermatitis", 
            "eczema", 
            "emollient", 
            "corticosteroid", 
            "flare"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tallinn", 
                        "country": "Estonia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tartu", 
                        "country": "Estonia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poitiers", 
                        "country": "France"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vilnius", 
                        "country": "Lithuania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pruszk\u00f3w", 
                        "country": "Poland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "P\u0142ock", 
                        "country": "Poland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u0141\u00f3d\u017a", 
                        "country": "Poland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bra\u015fov", 
                        "country": "Romania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Craiova", 
                        "country": "Romania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ia\u015fi", 
                        "country": "Romania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sibiu", 
                        "country": "Romania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Targu Mure\u015f", 
                        "country": "Romania"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Estonia", 
                "France", 
                "Lithuania", 
                "Poland", 
                "Romania"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Emollients in the Management of Atopic Dermatitis in Children: Prevention of Flares.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Comit\u00e9 de Protection des Personnes", 
                "Romania: Ethics Committee", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Lithuania: Bioethics Committee", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Poland: Ethics Committee", 
                "Estonia: The State Agency of Medicine", 
                "Estonia: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A flare is defined as following: measurable increased extend or intensity of lesions in less than 2 weeks under continued treatment corresponding to a significant increase in medical score  (> 25%) or to the introduction of a new line of therapy(topical corticosteroid).", 
            "measure": "Percentage of patients with at least one flare over the treatment period", 
            "safety_issue": "No", 
            "time_frame": "12 weeks of treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779258"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}